CA-RAFTR
16.3.2020 19:02:07 CET | Business Wire | Press release
Silicon Valley-based higher ed tech company Raftr announced today that it will offer its messaging and notifications platform free of charge through July 1, 2020 to colleges and universities, many of which are facing disruption and dislocation as a result of COVID-19 concerns. Each institution’s network is entirely private, limited to that community’s constituents.
The app facilitates immediate and direct communication between college administrations and their students in a mobile-first platform, enabling instant direct messaging to students’ mobile devices.
“Our partner institutions are facing a rapidly evolving COVID-19 outbreak, forcing unprecedented disruption on campuses and in remote learning environments,” Raftr Founder & CEO Sue Decker says. “The right thing to do is to offer our support. Raftr enables immediate communication between universities and their students, faculty, staff, and even parents, anywhere in the world. Exceptionally fast to implement, the interactive, flexible and coordinated communication platform can stand-alone or supplement email communication.”
Raftr enables group administrators to send custom push notifications directly to students’ and parents’ mobile devices, highlighting important updates about issues related to COVID-19, including online learning, study abroad cancellations or updates, academic information, and more.
Key features and customization options for different campus constituents include:
Administration:
- Public and private chat channels for sharing information, and Q&A in real time.
- Optional automatic posting of existing COVID-19 updates from authenticated sources, including CDC, the WHO, and/or existing university sources.
- Curated organization of all past communications for easy discovery and access.
Faculty:
- Ability to host real-time, virtual discussions and “office hours” in private channels for online courses, easily discoverable by students.
- Creation of an online lecture calendar with days / times of courses and ability to link directly to Zoom, Hangouts, or other online learning platforms.
- Direct and group chat options to stay connected to students one-on-one or in class settings.
- Ability to add links to important teaching materials.
Students:
- Creation of digital communities that mirror those on campus, including classes, student groups, social groups, and volunteer organizations.
- Ability to create unlimited public or private groups to maintain student organization communication and planning.
- Access to group chats, topic channels, direct messaging, photos & videos, polls and more.
Decker says the free use of the platform will be granted through July 1. To be eligible, administrators are asked to submit a request to enable their community and attend a one-hour online training session for any staff members who will be posting updates in the platform. Those staff members will be given access to Raftr ProTools, including the ability to send custom push notifications with important updates.
Online Request Form
Submit a request
Connect on Social
Twitter
LinkedIn
Facebook
About Raftr
Raftr promotes the power of belonging by building dynamic and safe digital communities through an intuitive student-centric communication platform. Each enabled school’s experience will be accessible only by that institution’s students, faculty, staff and parents, creating a private, curated, and trusted network. Raftr’s solutions cover every stage of undergraduate and alumni life, with packages for News & Events, Residence Life, Club & Groups / Academic Departments, and Orientation. The platform is available via mobile applications and website, and primary features include events, messaging, push notifications, polls and more. Additional information is available at https://pro.raftr.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200316005649/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
